Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

A Coefficient of Agreement for Nominal Scales

Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398

Statistical Methods for Rates and Proportions

Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005

Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S.

Toutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,547

The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study

Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906

Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study

Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30

Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555

Physicians' and patients' choices in evidence based practice

Haynes, R. B., Devereaux, P. J., & Guyatt, G. H. (2002) · BMJ · doi:10.1136/bmj.324.7350.1350 · Cited by 534

Correlation of patient and caregiver ratings of cancer pain

Grossman, S. A., Sheidler, V. R., Swedeen, K., Mucenski, J. W., & Piantadosi, S. (1991) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(91)90518-9 · Cited by 434

Methods for implementing and reporting the Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events to measure patient‐reported adverse events in cancer clinical trials

Dueck, A. C., Thanarajasingam, G., Rogak, L. J., Mazza, G. L., Langlais, B., Noble, B. N., Ginos, B., Mead‐Harvey, C., Yee, C., Lee, M. K., et al. (2025) · Cancer · doi:10.1002/cncr.35951 · Cited by 13

Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting

Rasschaert, M. A., Helsen, S., Rolfo, C. D., Brussel, I. V., Ravelingien, J., & Peeters, M. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3186-2 · Cited by 13

Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment

Andrillon, A., Biard, L., & Lee, S. M. (2023) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2023.2236216 · Cited by 13

Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

Dickson, N. R., Beauchamp, K. D., Perry, T. S., Roush, A., Goldschmidt, D., Edwards, M. L., & Blakely, L. J. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00700-4 · Cited by 14

Integrating PROs into the clinic — overall survival benefit or not, it's worth the trouble

Sperti, E., & Maïo, M. D. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.109 · Cited by 13

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Wang, T. Q., Samuel, J. N., Brown, M. C., Vennettilli, A., Solomon, H., Eng, L., Liang, M., Gill, G., Merali, Z., Tian, C., et al. (2018) · Oncology and Therapy · doi:10.1007/s40487-018-0065-7 · Cited by 15

Intraoperative Sentinel Events in the Era of Surgical Safety Checklists: Results of a National Survey

Cramer, J. D., Balakrishnan, K., Roy, S., Chang, C. W. D., Boss, E. F., Brereton, J. M., Monjur, T. M., Nussenbaum, B. A., & Brenner, M. J. (2020) · OTO Open · doi:10.1177/2473974x20975731 · Cited by 13

Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study

Brusniak, K., Feißt, M., Sebesteny, L., Hartkopf, A. D., Graf, J., Engler, T., Schneeweiß, A., Wallwiener, M., & Deutsch, T. M. (2021) · JMIR Cancer · doi:10.2196/25776 · Cited by 11

Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure

Feldman, E., Pos, F. J., Smeenk, R. J., van der Poel, H. G., van Leeuwen, P., de Feijter, J. M., Hulshof, M. C. C. M., Budiharto, T., Hermens, R., de Ligt, K. M., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100775 · Cited by 13

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial

Schwentner, L., Harbeck, N., Singer, S., Eichler, M., Rack, B. K., Forstbauer, H., Wischnik, A., Scholz, C., Huober, J., Friedl, T. W. P., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.03.003 · Cited by 13

Systematic Review of Adverse Events Reporting in Clinical Trials Leading to Approval of Targeted Therapy and Immunotherapy

Bossi, P., Botta, L., Bironzo, P., Sonetto, C., Musettini, G., Sbrana, A., Giannantonio, V. D., Locati, L. D., Maïo, M. D., & Antonuzzo, A. (2019) · Future Oncology · doi:10.2217/fon-2018-0772 · Cited by 13

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

Patel, M. P., Woodring, S., Randazzo, D. M., Friedman, H. S., Desjardins, A., Healy, P. N., Herndon, J. E., McSherry, F., Lipp, E., Miller, E., et al. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-05039-x · Cited by 13

Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement

Llovet, J. M., Mauro, E., Rimassa, L., Mazzaferro, V., Pinter, M., Kelley, R. K., Chan, S. L., Kulik, L., Pillai, A. A., Roberts, L. R., et al. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01160-z · Cited by 13

SystematiC nurse-led cONsultations based oN Electronic patient-reported outcome among women with ovarian- or endometrial Cancer during chemoTherapy – protocol for the CONNECT study

Christiansen, M. G., Jarden, M., Bager, L., Mirza, M. R., Pappot, H., & Piil, K. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2046850 · Cited by 12

Patient-Reported Outcome and Experience Measures in Advanced Nursing Practice: What Are Key Considerations for Implementation and Optimized Use?

Drury, A., Boland, V., & Dowling, M. (2024) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2024.151632 · Cited by 14

A randomized trial of the impact of symptom monitoring using an electronic patient-reported outcome app on health-related quality of life in postmenopausal breast cancer patients receiving adjuvant endocrine therapy

Okuyama, H., Takada, F., Taira, N., & Nakamura, S. (2024) · Breast Cancer · doi:10.1007/s12282-024-01592-4 · Cited by 14

Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials

Bandos, H., Torres‐Saavedra, P. A., Culakova, E., Gunn, H., Lee, M. K., Duan, F., Cecchini, R. S., Unger, J. M., Dueck, A. C., & Steingrimsson, J. A. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae047 · Cited by 11

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy

East Japan Chesters Group, Miya, T., Kobayashi, K., Hino, M., Ando, M., Takeuchi, S., Seike, M., Kubota, K., & Gemma, A. (2016) · SpringerPlus · doi:10.1186/s40064-016-3769-x · Cited by 12

Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study

Webster, E., Burke, W. M., Ware, H. M., Jones, B. A., Vattakalam, R. M., Tergas, A. I., Wright, J. D., & Hou, J. Y. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.008 · Cited by 12

E-santé, digitalisation ou transformation numérique : impact sur les soins de support en oncologie

Seguin, L., & Tassy, L. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.08.015 · Cited by 16

Physicians’ Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Efficace, F., Patriarca, A., Luppi, M., Potenza, L., Caocci, G., Tafuri, A., Fazio, F., Cartoni, C., Petrucci, M. T., Carmosino, I., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.826040 · Cited by 12

A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014–2018)

Gnanasakthy, A., Russo, J., Gnanasakthy, K., Harris, N., & Castro, C. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106860 · Cited by 12

Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer

Wages, N. A., Nelson, B. A., Kharofa, J. R., & Meier, T. M. (2022) · The International Journal of Biostatistics · doi:10.1515/ijb-2022-0023 · Cited by 14

Implementation and first results of a tablet-based assessment referring to patient-reported outcomes in an inpatient cancer care unit

Schuler, M. K., Trautmann, F., Radloff, M., Hentschel, L., Petzold, T., Eberlein-Gonska, M., Ehninger, G., & Schmitt, J. M. (2017) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2017.03.007 · Cited by 12

Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer

Chan, Y., Jheng, Y.-W., Wang, P.-J., Chen, C.-Y., Lin, M., & Wang, Y. (2019) · Clinical journal of oncology nursing · doi:10.1188/19.cjon.494-501 · Cited by 12

Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy

Brunello, A., Galiano, A., Schiavon, S., Nardi, M., Feltrin, A., Pambuku, A., Toni, C. D., Col, A. D., Lamberti, E., Pittarello, C., et al. (2022) · Cancers · doi:10.3390/cancers14102568 · Cited by 12

Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial

Wintner, L. M., Sztankay, M. J., Abdel‐Razeq, H., Hamdan-Mansour, R. A., Caocci, G., Mouillet, G., Kikawa, Y., Shibata, N., Krishnamurthy, M. N., Joshi, A., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00679-5 · Cited by 11

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR

Alger, E., Aiyegbusi, O. L., Dueck, A. C., Minchom, A., Pe, M. L., Peipert, J. D., Snyder, C. J., Symeonides, S. N., Wilson, R., Basch, E., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01625 · Cited by 13

Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer

Escudero‐Vilaplana, V., Bernal, E., Casado, G., Collado‐Borrell, R., Díez-Fernández, R., Román, A. B. F., Olías, C. F., González‐Cortijo, L., Fernandez, M. H., Marquina, G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.885910 · Cited by 11

Qualitative Study of Health Care Team Perception of the Benefits and Limitations of Remote Symptom Monitoring

Hendrix, E. K., Henderson, N. L., Padalkar, T. V., Kaufmann, T. L., Ingram, S. A., Dent, D., Huang, C.-H. S., Dionne-Odom, J. N., Weiner, B. J., Howell, D., et al. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00593 · Cited by 10

Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study

Smet, S., Spampinato, S., Pötter, R., Jurgenliemk-Schulz, I. M., Nout, R. A., Chargari, C., Mahantshetty, U. M., Sturdza, A. E., Šegedin, B., Bruheim, K., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.11.022 · Cited by 11

Oral Mucosa in Cancer Patients—Putting the Pieces Together: A Narrative Review and New Perspectives

Reuss, J. M., Alonso-Gamo, L., Garcia-Aranda, M., Reuss, D., Albi, M., Albi, B., Vilaboa, D. R., & Rodríguez-Vilaboa, B. (2023) · Cancers · doi:10.3390/cancers15133295 · Cited by 11

Gastrointestinal toxicities from targeted therapies

Bossi, P., Lucchesi, M., & Antonuzzo, A. (2015) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000128 · Cited by 11

Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events

Speck, R. M., Lenderking, W. R., & Shaw, J. W. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-018-0063-4 · Cited by 11

Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

Ooki, A., Morita, S., Tsuji, A., Iwamoto, S., Hara, H., Tanioka, H., Satake, H., Kataoka, M., Kotaka, M., Kagawa, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3564 · Cited by 13

Editorial: The Patient Knows Best: Incorporating Patient-Reported Outcomes Into Routine Clinical Care

Nipp, R. D., & Temel, J. S. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx044 · Cited by 11

Mobile Electronic Patient-Reported Outcomes and Interactive Support During Breast and Prostate Cancer Treatment: Health Economic Evaluation From Two Randomized Controlled Trials

Crafoord, M.-T., Ekstrand, J., Sundberg, K. K., Nilsson, M. I., Fjell, M., & Langius‐Eklöf, A. (2025) · JMIR Cancer · doi:10.2196/53539 · Cited by 10

Patient-centered dosing: oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)

Loeser, A. L., Gao, L., Bardia, A., Burkard, M. E., Kalinsky, K. M., Peppercorn, J. M., Rugo, H. S., Carlson, M., Cowden, J., Glenn, L. K., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06755-5 · Cited by 11

Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review

Maring, J. G., Eijsink, J. F. H., Tichelaar, F. D., Worawutputtapong, P., Postma, M. J., Touw, D. J., & de Groot, J. W. B. (2023) · Cancers · doi:10.3390/cancers15041135 · Cited by 10

The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma

Parreira, S., Burns, K. H., Moldawer, N. P., Zomordian, N., Bandali, N., Virdee, K., Walsh, M. K., Kelly, D. M., Rao, D., Teresi, R. E., et al. (2023) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2023.151545 · Cited by 11

Potential Patient-Reported Toxicities With Disulfiram Treatment in Late Disseminated Lyme Disease

Trautmann, A., Gascan, H., & Ghozzi, R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00133 · Cited by 10

Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials

Basch, E., Thanarajasingam, G., & Dueck, A. C. (2022) · Clinical Trials · doi:10.1177/17407745221093922 · Cited by 10

Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?

Sparano, F., Aaronson, N. K., Cottone, F., Piciocchi, A., Sala, E. L., Anota, A., Deliu, N., Kieffer, J. M., & Efficace, F. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0092 · Cited by 10

Initiatives for education, training, and dissemination of morbidity assessment and reporting in a multiinstitutional international context: Insights from the EMBRACE studies on cervical cancer

Kirchheiner, K., Smet, S., Spampinato, S., Jensen, N. B. K., Vittrup, A. S., Fokdal, L. U., Najjari-Jamal, D., Westerveld, H. G., Lindegaard, J. C., Kirisits, C., et al. (2020) · Brachytherapy · doi:10.1016/j.brachy.2020.08.011 · Cited by 10

The Roles of Nurses in Hematopoietic Cell Transplantation for the Treatment of Leukemia in Older Adults

Fauer, A. J., Choi, S. W., & Friese, C. R. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.150960 · Cited by 9

A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients

Petersen, S. E., Thorsen, L. B. J., Hansen, S., Petersen, P. M., Lindberg, H., Moe, M., Petersen, J. B., Muren, L. P., Høyer, M., & Bentzen, L. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1979246 · Cited by 9

Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab

Tan, J. Q. E., Abuhelwa, A. Y., Badaoui, S., Modi, N. D., Wiese, M. D., McKinnon, R. A., Sorich, M. J., & Hopkins, A. M. (2021) · Bladder Cancer · doi:10.3233/blc-211613 · Cited by 9

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer

Zaim, R., Redekop, K., & Groot, C. A. U. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101418 · Cited by 9

Novel Clinical Trial Designs in Neuro-Oncology

Saraf, A., Trippa, L., & Rahman, R. M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01284-x · Cited by 9

Isotonic Phase I Cancer Clinical Trial Design Utilizing Patient-Reported Outcomes

Wages, N. A., & Lin, R. (2023) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2023.2288013 · Cited by 10

Implementing a Clinical Pathway for Needs Assessment and Supportive Care Interventions

Stout, N. L., Alfano, C. M., Liu, R., Dixit, N., & Jefford, M. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00482 · Cited by 9

Exploratory Factor Analysis of NRG Oncology's University of Washington Quality of Life Questionnaire—RTOG Modification

Pugh, S. L., Wyatt, G. K., Wong, R. K. W., Sagar, S. M., Yueh, B., Singh, A. K., Yao, M., Nguyen‐Tan, P. F., Yom, S. S., Cardinale, F. S., et al. (2016) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2016.11.002 · Cited by 9

Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients

Nielsen, L. K., Klausen, T. W., Jarden, M., Frederiksen, H., Vangsted, A. J., Do, T., Kristensen, I. B., Frølund, U. C., Andersen, C. L., Abildgaard, N., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13175 · Cited by 9

Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review

Marandino, L., Vignani, F., Buttigliero, C., Gamba, T., Necchi, A., Tucci, M., & Maïo, M. D. (2020) · Cancers · doi:10.3390/cancers12092568 · Cited by 10

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial

Minchom, A. R., Tan, A. C., Massarelli, E., Subbiah, V., Boni, V., Robinson, B. G., Wirth, L. J., Hess, L. M., Jen, M., Kherani, J. F., et al. (2021) · The Oncologist · doi:10.1002/onco.13976 · Cited by 9

Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program

Collomb, B., Dubromel, A., Caffin, A. G., Herledan, C., Larbre, V., Baudouin, A., Cerutti, A., Couturier, L., Maire, M., Karlin, L., et al. (2022) · Cancers · doi:10.3390/cancers14030660 · Cited by 9

PLAG alleviates cisplatin-induced cachexia in lung cancer implanted mice

Kim, G. T., Kim, E. Y., Shin, S., Lee, H., Lee, S. H., Park, K., Sohn, K., Yoon, S. Y., & Kim, J. W. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101398 · Cited by 9

Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

Schroeder, K., Rizzieri, T., Lion, R. R., Mtenga, N., Gisiri, M., McFatrich, M., & Reeve, B. B. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00598-4 · Cited by 9

Toxicity and quality of life in published clinical trials for advanced lung cancer

Zwitter, M. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4214-1 · Cited by 9

Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types

King‐Kallimanis, B. L., Lederer, N. M., Kim, J., Nair, A., Horodniceanu, E. G., Bhatnagar, V., & Kluetz, P. G. (2021) · Value in Health · doi:10.1016/j.jval.2021.04.1279 · Cited by 9

Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance

Baldo, P., Fornasier, G., Francescon, S., Ferrarin, E., Truccolo, I., & Paoli, P. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.7613 · Cited by 9

Payer-Imposed Quantity Limits for Antiemetics: Everybody Hurts

Haque, W. Z., Sedhom, R., Chino, F. L., Royce, T. J., & Gupta, A. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00500 · Cited by 9

Recommendations for radiotherapy quality assurance in clinical trials

Nielsen, C. P., Samsøe, E., Offersen, B. V., Lorenzen, E. L., Persson, G. F., Mortensen, H. R., Nissen, H. D., Vogelius, I. R., Kallehauge, J. F., Muren, L. P., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.110950 · Cited by 8

Use of patient-reported outcomes version of the common terminology criteria for adverse events in oncology clinical trials

Rogak, L. J., Forschmiedt, J. K., Basch, E., Mazza, G. L., Lee, M. K., Meek, E. A., Ginos, B., Langlais, B., Noble, B. N., Deal, A. M., et al. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101547 · Cited by 8

The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer

Harder, H., Shilling, V. M., May, S. F., Cella, D. F., Schmid, P., & Fallowfield, L. J. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05798-w · Cited by 8

Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events

Yang, S.-S., Chen, L., Liu, Y., Lu, H., Huang, B.-J., Lin, A., Sun, Y., Ma, J., Xie, F., & Mao, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08610-0 · Cited by 8

Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study

Offodile, A. C., DiBrito, S. R., Finder, J. P., Shete, S. S., Jain, S., Delgado, D. A., Miller, C. J., Davidson, E., Overman, M. J., & Peterson, S. K. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057693 · Cited by 10

Exploring differences in symptomatic adverse events assessment between nurses and physicians in the clinical trial setting

Liu, L., Liu, Z., Ma, C., Cheng, M., Xie, Y., Zhang, L., & Wang, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-32123-4 · Cited by 9

Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials

Boccaccino, A., Rossini, D., Raimondi, A., Carullo, M., Lonardi, S., Morano, F., Santini, D., Tomasello, G., Niger, M., Zaniboni, A., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.001 · Cited by 8

Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA

Ribbands, A., Boytsov, N. N., Bailey, A., Gorsh, B., Luke, E., & Lambert, A. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07836-x · Cited by 8

Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

Günther, M., Hentschel, L., Schuler, M. K., Müller, T., Schütte, K., Ko, Y., Schmidt‐Wolf, I. G. H., & Jaehde, U. (2023) · BMC Cancer · doi:10.1186/s12885-023-11115-7 · Cited by 8

Application of Patient-Reported Outcome Measurements in Adult Tumor Clinical Trials in China: Cross-Sectional Study

Jia, Y., Li, Q., Zhang, X. W., Yan, Y. N., Yan, S., Li, S., Li, W., Wu, X., Rong, H., & Liu, J. (2024) · Journal of Medical Internet Research · doi:10.2196/45719 · Cited by 8

A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer

Jordan, T., Nuamek, T., Fornacon-Wood, I., Califano, R., Coote, J. H., Harris, M., Mistry, H. B., Taylor, P., Woolf, D., & Finn, C. F. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1328871 · Cited by 9

Symptomatic adverse events of chemotherapy in breast cancer patients:Using CTCAE, PRO-CTCAE, and EORTC QLQ-C30

Arahori, H., Kondo, K., Imai, Y., Bando, T., Inoue, H., Sasa, S., & Takizawa, H. (2024) · The Journal of Medical Investigation · doi:10.2152/jmi.71.82 · Cited by 8

Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study

Marques, R. P., Heudtlass, P., Pais, H. L., Quintela, A., & Martins, A. P. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02924-0 · Cited by 8

Patient‐centered engagement and symptom/toxicity monitoring in the new era of tumor next‐generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms

Yanez, B. R., Bouchard, L. C., Cella, D. F., Sosman, J. A., Kircher, S. M., Mohindra, N. A., Cristofanilli, M., & Penedo, F. J. (2019) · Cancer · doi:10.1002/cncr.32030 · Cited by 8

Patient-Centered Outcomes in Radiation Oncology

Grewal, A. S., & Berman, A. T. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.08.012 · Cited by 8

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

On behalf of GEICAM, S. B. C. G., Barnadas, A., Muñoz-Mateu, M., Vila, M. M., Chacón, J. I., Cassinello, J., Antolín, S., Adrover, E., Ramos, M., Carrasco, E., et al. (2019) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-019-0161-y · Cited by 8

Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases

Rahimy, E., Dudley, S. A., von Eyben, R., Pollom, E. L., Seiger, K., Modlin, L. A., Wynne, J. F., Fujimoto, D. K., Jacobs, L. R., Chang, S. D., et al. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000868 · Cited by 8

A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer

Morrison, A. E., Marshall, R., McFadyen, A. K., Hutchison, C., Rice, A. M., Stirling, L., McIlroy, P., & Macpherson, I. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-13327-6 · Cited by 8

Clinical Trial Patient-reported Outcomes Data: Going Beyond the Label in Oncology

Hao, Y., Krohe, M., Yaworsky, A., Shields, A. L., Mazar, I., Foley, C., & GLOBE, D. R. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.010 · Cited by 8

Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)

Tanioka, H., Miyamoto, Y., Tsuji, A., Asayama, M., Shiraishi, T., Yuki, S., Kotaka, M., Makiyama, A., Shimokawa, M., Shimose, T., et al. (2018) · Oncology · doi:10.1159/000486624 · Cited by 8

Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting

Miya, T., Kondo, H., & Gemma, A. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1321-4 · Cited by 8

SOHO State of the Art Updates and Next Questions | Measuring Patient-Reported Outcomes (PROs) and Treatment Tolerability in Patients With Hematologic Malignancies

Major, A., Dueck, A. C., & Thanarajasingam, G. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.07.018 · Cited by 7

Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score

Sakayori, M., Ohashi, T., Momma, T., Kaneda, T., Nishimura, S., Sutani, S., Yamashita, S., & Shigematsu, N. (2017) · Brachytherapy · doi:10.1016/j.brachy.2017.04.241 · Cited by 7

Health-Related Quality of Life during Chemoradiation in Locally Advanced Rectal Cancer: Impacts and Ethnic Disparities

Lim, S. H.-S., Ip, E., Ng, W. L., Chua, W. M., Asghari, R., Roohullah, A., Descallar, J., Henderson, C., Spring, K. J., SOUZA, P. D., et al. (2019) · Cancers · doi:10.3390/cancers11091263 · Cited by 7

A Simplified Diagnostic Classification Scheme of Chemotherapy-Induced Peripheral Neuropathy

Huang, H.-W., Wu, P., Su, P.-F., Li, C.-I., Yeh, Y., Lin, P., Hsu, K., Shen, M., Chang, J., & Lin, C. K. (2020) · Disease Markers · doi:10.1155/2020/3402108 · Cited by 7

Evaluation of skin reactions during proton beam radiotherapy – Patient-reported versus clinician-reported

Möllerberg, M., Langegård, U., Johansson, B., Ohlsson‐Nevo, E., Fransson, P., Ahlberg, K., Nyström, P. W., & Sjövall, K. (2021) · Technical Innovations & Patient Support in Radiation Oncology · doi:10.1016/j.tipsro.2021.05.001 · Cited by 8

Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria

Beijers, A. J. M., Mols, F., van den Hurk, C. J., & Vreugdenhil, A. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1073352 · Cited by 7

Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT

Hughes, A. M., Landers, D., Arkenau, H., Shah, S., Stephens, R., Mahal, A., Simmons, M. N., Lemech, C., & Royle, J. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0335-4 · Cited by 7

Adverse events of targeted therapies reported by patients with cancer treated in primary care

Roger, S., Edeline, J., Campillo‐Gimenez, B., Ventroux, E., Bugat, M.-È. R., & Chapron, A. (2020) · European Journal of General Practice · doi:10.1080/13814788.2020.1846713 · Cited by 7

Patient-Reported Outcomes Bridge an Important Gap in Identifying Risk for Early Endocrine Therapy Discontinuation

Wagner, L. I. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab024 · Cited by 8

Integrating Geriatric Oncology into Clinical Pathways and Guidelines

Battisti, N. M. L., & Dotan, E. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_18 · Cited by 7

Chemotherapy-induced peripheral neuropathy

Beijers, T. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161213tp · Cited by 7

Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy

Lequesne, J., Joly, F., Péron, J., Ray-Coquard, I. L., Bessard, A. C. H., Selle, F., Berton-Rigaud, D., Follana, P., Fabbro, M., Lortholary, A. H., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7101 · Cited by 6

Incidence of cisplatin-induced ototoxicity in adult cancer patients based on audiometric confirmation of patient self-report

Voruz, F., Vuilleumier, A., Migliorini, D., Nacher-Soler, G., Rousset, F., Maesschalck, T. D., & Senn, P. (2023) · Frontiers in Audiology and Otology · doi:10.3389/fauot.2023.1239119 · Cited by 6

Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research

Yip, R., Arnolda, G., Lamprell, K., Easpaig, B. N. G., Chittajallu, R., Delaney, G. P., Olver, I., Liauw, W., & Braithwaite, J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007555 · Cited by 8

Patientenberichtete Endpunkte – die Bedeutung der subjektiven Patientenperspektive für Forschung und klinische Versorgung

Dinkel, A., & Jahnen, M. (2024) · Die Urologie · doi:10.1007/s00120-024-02405-4 · Cited by 4

Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): Type II Hybrid Implementation Study

Roberts, N. A., Pelecanos, A. M., Alexander, K. E., Wyld, D., & Janda, M. (2024) · Journal of Medical Internet Research · doi:10.2196/55841 · Cited by 6

Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer

Zschaeck, S., Zöphel, K., Seidlitz, A., Zips, D., Kotzerke, J., Baumann, M. A., Troost, E. G. C., Löck, S., & Krause, M. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.10.030 · Cited by 6

Symptomatic Toxicities Experienced During Anti-Cancer Treatment: Comparison of Patients' and Physicians' Reporting in Three Randomized Controlled Trials (Rcts)

Maïo, M. D., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., Placido, S. D., Ceribelli, A., Favaretto, A. G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu356.2 · Cited by 1

Doctors less likely than patients to report toxicity of cancer treatments, study shows

Mayor, S. (2015) · BMJ · doi:10.1136/bmj.h485 · Cited by 1

Under-reporting of subjective symptoms and its prognostic value. A pooled analysis of 12 cancer clinical trials.

Arenare, L., Liello, R. D., Placido, P. D., Gridelli, C., Morabito, A., Pignata, S., Nuzzo, F., Avallone, A., Maiello, E., Gargiulo, P., et al. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8309691

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

Gravis, G., Marino, P., Joly, F., Oudard, S. M., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.034 · Cited by 69

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

Perrone, F., Basch, E., Bryce, J., & Maïo, M. D. (2022) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/sc1k-1404